7 recruiting, 5 completed, 3 terminated, 2 unknown. 5 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 4.
Follow Castleman Disease: new trials by email Literature Review of Castleman Disease trials Research Report on Castleman Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease Ruxolitinib - Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease | Phase 2 | Recruiting | University of Pennsylvania | 14 | 2025-12-18 | 2026-04-22 |
| Nintedanib Treatment in Unicentric Castleman Disease Nintedanib - Castleman Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 13 | 2024-11-01 | 2024-10-15 |
| An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context Castleman Disease | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 65 | 2023-03-01 | 2024-12-06 | |
| HHV8 and Solid Organ Transplantation Diagnostic test for HHV8 exposure - HHV8, HHV8 Infection | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 250 | 2021-09-15 | 2024-05-07 | |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH No intervention - Multiple Myeloma, Amyloidosis | Recruiting | Peking University First Hospital | 2000 | 2021-07-01 | 2026-09-16 | |
| Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease Genetic testing - Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH) | Not applicable | Suspended | Case Comprehensive Cancer Center | 135 | 2021-06-18 | 2026-10-06 |
| AutoInflammatory Disease Alliance Registry (AIDA) No intervention is foreseen by the protocol. - Hereditary Autoinflammatory Diseases, Schnitzler Syndrome | Recruiting | University of Siena | 3500 | 2020-08-06 | 2025-07-10 | |
| Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease Sirolimus - Castleman Disease, Castleman's Disease, Multicentric | Phase 2 | Active not recruiting | University of Pennsylvania | 7 | 2019-09-25 | 2026-08-20 |
| Registry for Adults With Plasma Cell Disorders (PCD's) Multiple Myeloma, Amyloidosis | Recruiting | UNC Lineberger Comprehensive Cancer Center | 2000 | 2018-02-09 | 2025-11-20 | |
| Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease Human Immunodeficiency Virus, Castleman's Disease | Recruiting | National Cancer Institute (NCI) | 280 | 2017-12-20 | 2026-10-16 | |
| International Registry for Patients With Castleman Disease Castleman Disease, Castleman's Disease | Recruiting | University of Pennsylvania | 1000 | 2016-10-01 | 2026-03-03 | |
| Castleman Disease Collaborative Network Biobank Sample Collection - Castleman Disease, Castleman's Disease | Withdrawn | Castleman Disease Collaborative Network | 2016-06-01 | 2018-07-31 | ||
| Unlock the Cell: Castleman's Disease Flow Cytometry Study Blood draw/buccal swab - Castleman Disease, Angiofollicular Lymphoid Hyperplasia | Completed | University of Pennsylvania | 130 | 2016-02-01 | 2020-03-26 | |
| Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Nelfinavir - Non-Hodgkin Lymphoma, Hodgkin Lymphoma | Early Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 | 2014-07-01 | 2016-06-10 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 154 | 2012-10-16 | 2026-05-15 |
| Tocilizumab for KSHV-Associated Multicentric Castleman Disease Zidovudine, Tocilizumab, Valganciclovir (VGC) - Castleman Disease, Multicentric Castleman Disease | Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2011-09-13 | 2020-10-27 |
| Unicentric Form of Castleman Disease - Surgery Therapy Benefit surgery type/exstirpation/debulking - Castleman Disease, Unicentric Castleman Disease | Completed | Charles University, Czech Republic | 20 | 2011-01-01 | 2022-06-30 | |
| Dose-escalation Study of Oral CX-4945 CX-4945 oral formulation - Advanced Solid Tumors, Breast Cancer | Phase 1 | Unknown | Cylene Pharmaceuticals | 55 | 2009-02-01 | 2011-06-15 |
| Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease Valganciclovir - Giant Lymph Node Hyperplasia | Phase 4 | Withdrawn | University of Washington | 2008-12-01 | 2017-04-18 | |
| A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment tocilizumab [RoActemra/Actemra] - Castleman's Disease | Phase 1 | Completed | Hoffmann-La Roche | 3 | 2006-08-01 | 2016-11-02 |
Showing 20 of 22. Sign in to see all of them.
Multi-centric Castleman's Disease (5) · Sarcoma, Kaposi (5) · Macular dystrophy, corneal type 1 (4) · Multiple Myeloma (4) · Acquired Immunodeficiency Syndrome (2) · Amyloidosis (2) · Breast Neoplasms (2) · Cryoglobulinemia (2) · Hyperplasia (2) · Leukemia, Plasma Cell (2) · Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · POEMS Syndrome (2) · Sarcoma (2)
Hemic and Lymphatic Diseases (22) · Immune System Diseases (22) · Immunoproliferative Disorders (22) · Lymphatic Diseases (22) · Lymphoproliferative Disorders (22) · Neoplasms by Histologic Type (10) · Neoplasms (8) · Neoplasms, Connective and Soft Tissue (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Cardiovascular Diseases (5) · DNA Virus Infections (5) · Hematologic Diseases (5) · Herpesviridae Infections (5) · Infections (5)
Sirolimus (2) · Valganciclovir (2) · tocilizumab (2) · Bevacizumab (1) · Cetuximab (1) · Diagnostic Tests, Routine (1) · Disulfides (1) · Genetic Testing (1) · Immunoglobulin G (1) · Nelfinavir (1) · Rituximab (1) · Specimen Handling (1) · Valproic Acid (1) · Zidovudine (1) · nintedanib (1)
University of Pennsylvania (4) · National Cancer Institute (NCI) (2) · Assistance Publique - Hôpitaux de Paris (1) · Case Comprehensive Cancer Center (1) · Castleman Disease Collaborative Network (1) · Centocor, Inc. (1) · Charles University, Czech Republic (1) · Cylene Pharmaceuticals (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Hoffmann-La Roche (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · M.D. Anderson Cancer Center (1) · Peking University First Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (14) · Italy (3) · China (2) · Algeria (1) · Australia (1) · Belgium (1) · Brazil (1) · Colombia (1) · Egypt (1) · Germany (1) · Greece (1) · India (1) · Iran (1) · Libya (1) · Martinique (1)
Joshua Brandstadter, MD, PhD, MSc (3) · Robert Yarchoan, M.D. (2) · Corey Casper, MD, MPH (1) · David C Fajgenbaum, MD, MBA, MSc (1) · Eric Oksenhendler, M.D. (1) · Pier Luigi Zinzani, MD (1) · Richard Ambinder, MD (1) · Sarina A Piha-Paul (1) · Sascha Tuchman, MD (1) · Sudipto Mukherjee, MD, PhD (1) · Vera Krymskaya, PhD, MBA (1)
PMID 31408438, PMID 32206779, PMID 33284946, PMID 29675946, PMID 30181172, PMID 32106302, PMID 32276276, PMID 32376796, PMID 33377129, PMID 33709329, PMID 34265103, PMID 34438448, PMID 35104370, PMID 35463015, PMID 35488725, PMID 35507638, PMID 35755024, PMID 35831701, PMID 35899212, PMID 35935379, PMID 36160138, PMID 36433996, PMID 36881285, PMID 37311055, PMID 37517110, PMID 37635628, PMID 37656441, PMID 37740179, PMID 37867418, PMID 38168727, PMID 38206518, PMID 39044861, PMID 40175882, PMID 41389341, PMID 41845569, PMID 42444147